Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123538 | 0.98 | SLC6A3 (0.61) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| SCHEMBL377276 | 0.91 | CYP17A1 (0.63) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| Ammonia Solution, Strong SCHEMBL10389261 | 0.86 | HTR2A (0.56) | POLBLMNAHTR2AHRH1TDP1 | |
| Ammonia Solution, Strong SCHEMBL5683105 | 0.86 | HTR2A (0.56) | POLBLMNAHTR2AHRH1TDP1 | |
| Ammonia Solution, Strong SCHEMBL6000279 | 0.84 | CYP17A1 (0.52) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| SCHEMBL54346 | 0.83 | HTR2A (0.59) | POLBLMNAHTR2AHRH1TDP1 | |
| Ammonia Solution, Strong SCHEMBL5999950 | 0.83 | CYP17A1 (0.57) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| Ammonia Solution, Strong SCHEMBL6000241 | 0.82 | CYP17A1 (0.51) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| Ammonia Solution, Strong SCHEMBL5999442 | 0.82 | CYP17A1 (0.51) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 | |
| Ammonia Solution, Strong SCHEMBL6000280 | 0.82 | CYP17A1 (0.51) | SLC6A3SLC6A2SLC6A4CYP17A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | SLC6A3 789/4885SLC6A2 1494/4885SLC6A4 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.